Pushing Cancer Treatment into the Future
Lumitron Technologies, a company housed in the UC Irvine Research Park and co-founded by Professor Christopher Barty of the UC Irvine Department of Physics & Astronomy, is developing a novel X-ray and electron beam machine called HyperVIEW™ that aims to selectively image cancer in the body and eliminate it while minimizing damage to surrounding tissue.
“The machine has now generated electron beams that can be used to treat cancer anywhere in the human body and x-ray beams that follow the same path as the electrons that can image cancer at 100 times beyond the resolution of conventional clinical systems,” said Barty. “The holy grail is that ultimately you will have the ability to guide your cancer treatment in ways that nobody’s ever been able to do before.” HyperVIEW™ is a fourth-generation, laser-Compton X-ray technology Barty started developing when he was a scientist at Lawrence Livermore National Laboratory. HyperVIEW™ X-rays will “allow you to image soft tissues at potentially cellular levels, something that has only ever been done at billion-dollar synchrotron facilities,” Barty said, which means Lumitron’s technology could one day both track and treat cancer at the cellular level in the human body. The company plans to have FDA approval for initial, precision cancer imaging applications by late 2025 and moved HyperVIEW™ to pre-clinical cancer treatment studies late this summer. “With this technology, we may eliminate the need to ever remove a breast or prostate again,” said Barty.
Click here to read the 2024 UC Irvine Physical Sciences Dean’s Report.
